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Abstract
In solid organ transplant patients, it is important to maintain a fine balance between preventing
rejection and reducing adverse effects. Several immunosuppressive agents such tacrolimus,
cyclosporine, sirolimus and everolimus require therapeutic drug monitoring. The study of
germline variation of the genome has opened novel opportunities to individualize therapy. Among
the currently available immunosuppressive agents, cyclosporine, tacrolimus and mycophenolic
acid are in vitro substrates of the UGT1A and 2B families of glucuronidation enzymes.
Mycophenolic acid, either given as mycophenolate mofetil or mycophenolate sodium, is the most
frequently used antiproliferative immunosuppressant. Mycophenolic acid is a prodrug which is
rapidly de-esterified in the gut wall, blood, liver and tissue to the active moiety, mycophenolic
acid (MPA). MPA undergoes significant hepatic metabolism to several metabolites. The 7-
hydroxyglucuronide MPA is the major metabolite and is inactive. This paper reviews the current
status of the genetic associations between germline UGT variants and the pharmacokinetics and
pharmacodynamics of mycophenolic acid. Our conclusive assessment of the studies conducted so
far is that these germline markers are not ready to be used in the clinic to individualize
mycophenolic acid dosing and improve outcome. Novel approaches are required to identify new
genetic determinants of outcomes in transplantation.
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1. Introduction
In solid organ transplantation, combination immunosuppressive therapy is used for
prevention of organ rejection. Several agents such as calcineurin inhibitors (cyclosporine or
tacrolimus), mTOR inhibitors (sirolimus or everolimus), antiproliferatives (azathioprine or
mycophenolic acid) and corticosteroids are used in combination. Calcineurin inhibitors and
antiproliferatives serve as the foundation of this therapy [1].
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These agents are very effective in minimizing organ rejection and maintaining prolonged
graft survival. However, they also can produce serious and life threatening toxicities such as
nephrotoxicity, neurotoxicity, electrolyte disturbances, hematologic abnormalities and
infection. Therefore, it is important to maintain a delicate balance between preventing
rejection and minimizing adverse effects. Several of these immunosuppressive agents such
tacrolimus, cyclosporine, sirolimus and everolimus require therapeutic drug monitoring.
This is due to their narrow therapeutic index, poor correlation between dose and response
and toxicity, significant pharmacokinetic inter-and intra-patient variability and changes in
these parameters and changes in organ function over time [2].
The study of germline variation of the genome has opened novel opportunities to
individualize therapy. Many of the available germline markers that can be used in the clinic
relate to genes coding for drug metabolizing enzymes involved in the activation or
inactivation of parent drugs [3]. Among those, the UDP-glucuronosyltransferases belong to
a superfamily of phase II conjugation enzymes, the genetic variation of which has been
extensively studied [4]. Two superfamilies have been described according to sequence
homology, UGT1 and UGT2.
As members of the UGT1A and UGT2B families are the only UGTs involved in the
metabolism of immunosuppressive agents, we will focus on describing the UGT1A and
UGT2B families in this review. The UGT1A proteins are coded from a locus mapping to
chromosome 2q37 and spanning more than 218 kb [4]. The UGT1A gene complex is
comprised of 13 unique first exons which undergo alternative splicing with common exons
2–5. The lead exon at the 5′ end specifies the substrate-binding domain in the amino-
terminal region. The common exons at the 3′ end encode the UDP-glucuronic acid-accepting
domain. In the UGT1A locus, there are 9 functional enzymes designated as UGT1A1 and
UGT1A3-UGT1A10, while UGT1A2p, UGT1A11p, UGT1A12p and UGT1A13p are
pseudogenes [5]. The UGT2B enzymes are encoded by separate genes located at 4q13. Each
UGT2 gene consists of six exons. Among the various UGT2B isoforms (UGT2B4,
UGT2B7, UGT2B28, UGT2B10, UGT2B11, UGT2B15, UGT2B17), UGT2B7 is the
enzyme that has been studied the most in pharmacogenetics [6].
Among the currently available immunosuppressive agents, cyclosporine, tacrolimus and
mycophenolic acid are in vitro substrates of the UGT1A and 2B families of UGTs. For
cyclosporine, glucuronidation is generally considered a minor pathway [7]. Tacrolimus
undergoes glucuronidation via UGT1A4 in vitro but the significance of this pathway and its
contribution to inter-patient pharmacokinetic variability is not known [8].
Mycophenolic acid, either given as mycophenolate mofetil (MMF) or mycophenolate
sodium (EC-MPS), is the most frequently used antiproliferative immunosuppressant. MMF
has replaced azathioprine based on major clinical trials indicating improved outcomes
compared to azathioprine or placebo [9]. The majority of transplant recipients receive MMF
or EC-MPS after transplant [10]. Both agents are similar in terms of pharmacology and
adverse effects [11]. The major pharmacologic effect of MPA is inosine monophosphate
dehydrogenase (IMPDH) inhibition. The most common adverse effects, which are
experienced in at least 30% of patients, include gastrointestinal and bone marrow toxicities
and infection. The majority of clinical pharmacogenetic and pharmacokinetic data have been
published with MMF [12].
MMF is a prodrug which is rapidly de-esterified in the gut wall, blood, liver and tissue to the
active moiety, mycophenolic acid (MPA). EC-MPS is enteric coated and absorbed as MPA.
MPA is metabolized in the gastrointestinal tract and liver via UGTs. MPA undergoes
significant hepatic metabolism to several metabolites. The 7-hydroxyglucuronide MPA
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(MPAG) is the major metabolite and is inactive. Two other minor metabolites are produced,
the inactive phenolic glucoside and the acyl-glucuronide (AcMPAG), the latter with some
pharmacologic and toxicologic effects [13]. These metabolites are excreted via bile into the
intestine. MPAG undergoes enterohepatic recirculation via cleavage by bacterial
glucuronidases to MPA, which is subsequently reabsorbed back into the systemic
circulation. Ultimately, the majority of metabolites are renally eliminated [12].
MPA exhibits significant interpatient pharmacokinetic variability [12]. Several factors are
associated with MPA pharmacokinetic variability. These include age, sex, ethnicity, protein
binding, liver and renal function as well as drug interactions, time post transplant (affecting
the kinetics of MPA due to changes in protein binding and clearance) and the function of
drug transporters [14,15].
MPA is typically given as a fixed dose. However, because of the significant
pharmacokinetic variability, some studies have shown that total MPA area under the curve
(AUC 0–12 h) is correlated with outcomes such as early acute rejection [16,17]. However,
the correlation between total MPA AUC 0–12 h and toxicities is less clear [18]. Recently
several randomized studies comparing fixed dose versus concentration-controlled dosing
have been conducted with conflicting results [19,20]. There is conflicting data as well with
trough levels in relation to MPA efficacy and toxicity [14,21]. In addition, trough
concentrations are not very good correlates with AUC and their value of therapeutic drug
monitoring is debated [22,23].
Unlike the metabolism of other transplant immunosuppressives, glucuronidation plays a
significant role in MPA pharmacokinetics. UGTs 1A1, 1A7, 1A8, 1A9 and 1A10 are
important for MPA glucuronidation [24,25]. Hepatically-expressed UGT1A9 is responsible
for >50% of MPA metabolism to MPAG [21]. UGT1A8 and UGT1A10 are predominantly
located in the gastrointestinal tract and thought to play a minor role in MPA disposition.
MPA is also metabolized via UGT2B7 and UGT1A8, to AcMPAG which may contribute to
gastrointestinal and possibly hematologic toxicities [26].
UGT enzyme activity and several single nucleotide polymorphisms (SNPs) have been
shown to correlate with changes in protein expression and enzyme catalytic activity [24,27–
29]. Polymorphisms of these enzymes may have an influence and also contribute to MPA
interindividual variation in pharmacokinetics (see Table 1) and pharmacodynamic outcomes
(See Table 2).
2. UGT1A9 and MPA pharmacokinetics
The majority of studies examining the relationship between UGT polymorphisms and MPA
pharmacokinetics have involved UGTIA9 SNPs. These studies have been conducted
primarily in kidney transplant recipients. In the first reported study, in a Caucasian
population of 95 kidney transplant recipients, who received tacrolimus and steroids, a 50%
reduction in mean total MPA AUC 0–12 h and AUC 6–12 h (day 7 after transplant) was
seen in patients who were either carriers of UGT1A9 – 275T>A or – 2152C>T or both,
compared to noncarriers. This association was seen only in patients on 2 g/day compared to
1 g/day doses [16]. It is unclear why this association was seen with MPA dose. Potential
reasons for this finding could include differences in intestinal versus hepatic UGT1A9
activity, the influence of other untested UGT SNPs, other SNPs in genes playing a role in
MPA disposition, such as those coding for ABC and SLC transporters; the use of tacrolimus
which could exhibit dose dependent UGT inhibition; and the effect of renal dysfunction,
elevated MPAG concentrations and albumin changes during the early transplant period. This
dose effect has not been confirmed by other studies. Also in this study, covariates such as
sex, creatinine clearance, and liver dysfunction also influenced the variability in several
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pharmacokinetic parameters. These variables, along with these UGT1A9 SNPs, accounted
for 15–43% of the pharmacokinetic variability in MPA AUC. In a long-term study,
conducted over five years, involving 100 Caucasian kidney transplant recipients, the
UGT1A9 −275T>A or −2152C>T SNPs were associated with MPA AUC 0–12 h below the
suggested therapeutic target range. The impact of dose was not examined in this analysis
[17]. A smaller study, in 30 Caucasian kidney transplant recipients on tacrolimus, found an
association between these same SNPs and MPA AUC 0–12 h. Mean total MPA AUC 0–12 h
was 26% lower in carriers. This association was seen in patients who received doses of <2 g/
day. This suggests that there may not be a dose effect and that an association between SNP
and AUC 0–12 h could be seen at any dose. Although this requires further validation [30].
Other studies have found associations between these SNPs and MPA pharmacokinetic
parameters. However, this association may vary depending on concomitant
immunosuppressives such as cyclosporine and tacrolimus or sirolimus in combination with
MPA. The largest study to date was conducted in 338 kidney transplant patients, mostly
Caucasians, 176 of them were on tacrolimus and 163 on cyclosporine. Carriers of UGT1A9
−275T>A and −2152C>T who were receiving tacrolimus had a significantly lower MPA
AUC 0–12 h (day 3) than non-carriers. However, this effect was not seen for those receiving
cyclosporine [31]. In a study of 117 kidney and/or pancreas transplant recipients, either on
cyclosporine or tacrolimus without steroids, MPA trough levels (30 days after transplant)
were 70% lower in −275T>A and −2152C>T carriers in patients on cyclosporine. In contrast
to the previous study, there was no significant difference seen in patients on tacrolimus,
although the sample size of the patients on tacrolimus was much smaller, making it difficult
to draw conclusions about the lack of association in the tacrolimus arm [32]. Troughs, and
not AUCs, were evaluated and, as stated earlier, these parameters do not correlate very well
with each other. Another consideration in this study is that patients were not receiving
steroids, which have been shown to influence the disposition of MPA by reducing AUC
exposure [33,34]. In addition cyclosporine interacts with MPA. Cyclosporine can inhibit
MRP2, which is responsible for biliary excretion of MPAG and could ultimately affect MPA
concentrations and offset any increased UGT1A9 activity [35,36]. Other variables such as
renal function, MPA protein binding, and time post-transplant could contribute to these
contrasting study results.
Not all studies have found an association between these UGT SNPs and MPA
pharmacokinetic variability. In one study, 40 Caucasian kidney transplant patients on
cyclosporine without steroids treated with MMF were evaluated at 6 months after transplant.
No association was seen with UGT1A9 −275T>A or −2152C>T and pharmacokinetic
parameters [37]. However, this study was not adequately powered to show whether or not a
significant association exists.
Picard et al. reported on 115 kidney transplants on cyclosporine and steroids and 70 kidney
transplants on sirolimus or tacrolimus and steroids. MPA AUC 0–12 h was measured
between 3 and 6 months after transplant. There was no association seen with the −275T>A
and −2152C>T SNPs and this pharmacokinetic parameter across all groups [38].
Although data is conflicting about the influence of these two SNPs on MPA exposure, some
studies as noted above demonstrate a relationship within the first few days after transplant.
This may be an important consideration since acute rejection often occurs in the first few
days to weeks after transplant. It is also known that MPA exposure is lowest in the early
post transplant period. A loading dose approach over the first few days after transplant to
overcome this lower exposure has been suggested [21]. Recently, a study in 135 kidney
transplant recipients, receiving tacrolimus and steroids, was conducted to examine this
approach. The results indicate that an MMF loading dose significantly increased the number
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of patients who achieved a therapeutic MPA AUC 0–12 h by day 3 compared to those who
received a fixed dose without a loading dose. The incidence of adverse effects and acute
rejection, although lower, was not statistically different although stated power was not
achieved [39]. Unfortunately no genotyping was conducted, but it is worth considering that
apriori knowledge of the UGT1A9 −275T>A and −2152C>T SNPs, since they are
associated with reduced early MPA exposure, could potentially have improved on and
impacted these results. Unfortunately, there is no prospective study which has incorporated
this early use of genotyping.
Several other UGT1A9 SNPs and their association with MPA pharmacokinetic parameters
have also been investigated. Some studies have examined the role of UGT1A9 −98T>C
(UGT1A9*3). This SNP was associated with higher MPA AUC or trough concentrations in
patients treated with MMF [16,31,32,38]. For example, one study found that carriers had
MPA AUC which was 49% and 54% higher in patients on tacrolimus and cyclosporine
respectively compared to noncarriers [31]. Another study reported a similar finding only in
patients who received 1 g/day and not with 2 g/day but this was based on only 3 patients
with this polymorphism [16]. The frequency of this SNP in these studies and in Caucasians
in general is quite low (1.6–3%) making the interpretation of the genetic associations and its
utility difficult [40].
UGT1A9 I399 has also been examined, but no significant associations have been reported
[31,41].
UGT1A9 −440C>T and −331T>C SNPS have been also evaluated. These are in complete
linkage disequilibrium with each other [25]. In one study of 185 kidney transplants, on
MMF with either tacrolimus, cyclosporine or sirolimus, −440C>T was associated with a
shorter MPA Tmax but with no other pharmacokinetic parameter [38]. However, another
study in 40 kidney transplants on cyclosporine demonstrated lower MPA AUC 0–12 h at six
months after transplant in patients with either one of the two SNPs. In this study, glomerular
filtration rate (GFR) was inversely correlated with MPAG AUC 0–12 h [37]. High MPAG
levels can accumulate with reduced GFR, and are known to affect protein binding of MPA,
which is highly protein bound [12]. This ultimately can lead to an increase in MPA free
fraction, total MPA clearance, and a reduction in MPA AUC. This indirect effect could have
significantly influenced the results of this study, questioning the true contribution and
association of these SNPs with pharmacokinetic parameters.
Two UGT1A8 SNPs, 830G>A (UGT1A8*3) and 518C>G (UGT1A8*2) have been
evaluated for their relationship with MPA pharmacokinetics. Two studies, one in 117 kidney
and/or pancreas transplants and the other in 338 kidney transplants found no influence of the
830G>A (UGT1A8*3) SNP on MPA pharmacokinetics. Though these studies had relatively
large numbers of patients, few patients (4–7%) were carriers of these SNPs [31,32]. In the
study with 117 kidney and/or pancreas transplants, on MMF plus tacrolimus or cyclosporine
without steroids, MPA troughs were 60% higher in those who were carriers of 518C>G
(UGT1A8*2). This was seen in tacrolimus patients only. Whereas in the cyclosporine group,
troughs were 20% higher but this association was not significant [32]. In the study of 338
kidney transplants, those receiving cyclosporine with MMF and steroids who were *2/*2
had a mean MPA AUC 0–12 h that was 18% higher than wild-type patients. Those on
tacrolimus with MMF and steroids had a 13% higher mean MPA AUC 0–12 h, but this
association was not significant [31]. In contrast to these findings, in a study conducted in
185 recipients with tacrolimus or cyclosporine or sirolimus and steroids, a significantly
lower MPA exposure was seen in *2/*2 patients, receiving tacrolimus or sirolimus, whereas
no impact was seen in the patients on cyclosporine [38]. A study conducted in 72 Japanese
patients, treated with tacrolimus and steroids, saw no significant effect of this SNP on MPA
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pharmacokinetics [42]. Therefore, as with other UGT SNPs, conflicting results associated
with 518C>G (UGT1A8*2) have been reported. This could be due to study design issues
and other physiologic and pharmacologic parameters that have not been taken into account,
as well as other untested UGT SNPs.
3. UGT2B7 polymorphisms and MPA pharmacokinetics
UGT2B7 is responsible for the metabolism of MPA to AcMPAG, a minor metabolite. A few
studies have reported on the influence of either UGT2B7 −842G>A, −79G>A and −802C>T
(UGT2B7*2) polymorphisms. These SNPs are in complete linkage disequilibrium with each
other. In a study of 40 Caucasian kidney transplants treated with cyclosporine and steroids,
MPA AUC 0–12 h was not associated with −802C>T but carriers of this SNP did show a
higher MPA maximum concentration [37]. In three other studies, which included either
Caucasian, Japanese, or Chinese patients, no association with the −802C>T SNP and MPA
pharmacokinetics was reported [37,42,43]. In the study including 338 kidney transplants, no
influence of −842G>A and −79G>A on MPA pharmacokinetics was reported [31]. These
studies, which include both large and small number of patients, indicate that the tested
UGT2B7 gene variants have a minor effect on MPA pharmacokinetics.
4. UGT polymorphisms and MPAG pharmacokinetics
The major metabolite of MPA is MPAG. Its metabolism is mediated via UGTs 1A1, 1A6,
1A7, 1A8, 1A9 and 1A10, with the most significant contribution from UGT1A9 [40]. A
study in 80 Japanese transplant recipients was conducted to evaluate the influence of these
SNPs on MPAG pharmacokinetics. MPAG and MPA AUC 0–12 h and ratio of MPAG/
MPA AUC 0–12 h were measured on day 28 after transplant. There was no association
between these UGT1A SNPs and MPAG and MPA AUC 0–12 h and MPAG/MPA AUC 0–
12 h ratio [44]. In another study which included 40 Caucasian kidney transplants, no
association with UGT1A9 polymorphisms was found [37]. Two other studies found similar
nonsignificant results between UGT1A9 SNPs and MPAG pharmacokinetics [34,38]. One
of these studies by Picard et al. in 185 kidney transplant patients investigated the
relationship between MPAG trough, MPAG Cmax and MPAG AUC 0–9 h and UGT1A9
−275T>A, −2152C>T, −440C>T/−331T>C, 98C>T and UGT1A8 −518C>G. They did not
identify any significant associations [38]. A few studies have evaluated the influence of
UGT2B7 SNPs on MPAG AUC and found no association with this pharmacokinetic
parameter [34,37,43]. Therefore, with the available information, UGT polymorphisms do
not seem to play any significant role in MPAG disposition. MPAG variability could be due
to other important factors such as transporters and/or renal function.
5. UGT polymorphisms and AcMPAG pharmacokinetics
AcMPAG has been thought to contribute to side effects, such as gastrointestinal toxicity and
leukopenia, although solid clinical data is lacking [45]. AcMPAG is thought to cause
irreversible binding between plasma and tissue proteins and nucleic acids resulting in
cellular toxicity. AcMPAG also has proinflammatory activity [13]. AcMPAG, like MPAG,
is renally eliminated and concentrations are higher in patients with reduced renal function
[46,47]. Interindividual variation of AcMPAG concentrations exists, and this could be due,
in part, to polymorphisms in UGT2B7 and UGT1A8, the enzymes responsible for the
conversion of MPA to AcMPAG. A few studies have evaluated the influence of UGT2B7
SNPs and their association with AcMPAG disposition with conflicting results. One study
conducted in 46 Chinese kidney transplants found no association [44]. The other study in
332 kidney transplants (mostly of Caucasian origin) also found no association [48]. In
contrast to these studies, two other studies found that there was an influence of UGT2B7
polymorphisms. The first study was conducted in 92 kidney transplants (ethnicity not
Dupuis et al. Page 6













specified) on either cyclosporine, tacrolimus, or sirolimus in combination with MMF, and
decreasing steroid doses. Patients were evaluated during the first three months after
transplant. This study found that UGT2B7 −842G>A and −802C>T, which are in linkage
disequilibrium with each other, were associated with higher AcMPAG AUC 0–9 h. This
effect was seen only in the sirolimus group and not with cyclosporine or tacrolimus [34].
This association was not seen in the first week but only at 1 and 3 months. Creatinine
clearance was reported as not being different among groups. Steroid doses however were
higher in the first week, as well as the AcMPAG AUC compared to later times, suggesting
an inductive effect on MPA metabolism. This effect would be diminished as steroid dose
would be reduced with time. In addition, cyclosporine and tacrolimus could also affect
results by altering metabolite transport as drug doses are often reduced over time. As with
many studies, the number of patients with their respective genotype was also very small and
minimizes the power of this study and its conclusions. Another study was conducted in 68
thoracic, lung or heart transplants mostly of Caucasian origin who received MMF with
either cyclosporine or tacrolimus. This study looked at UGT1A9 and UGT2B7 SNPs and
MPA and AcMPAG pharmacokinetic parameters as well as outcomes (discussed in later
section). They did not find any association between UGT1A9 SNPs and MPA or AcMPAG
parameters. They did report that carriers of UGT2B7 −802T (*2) demonstrated 2.5–3.7 fold
higher AcMPAG AUC 0–12 h and AcMPAG/MPA ratios. Carriers of UGT2B7-138G>A
(*2g) had AcMPAG AUC and AcMPAG/MPA ratios that were 9.3–12.3 fold higher than
noncarriers [49]. An important consideration is whether or not renal function, which is often
altered or reduced in transplant recipients, could have influenced these results. It is known
that reduced renal function is associated with the accumulation of the AcMPAG metabolite.
The only assessment of renal function in this study was serum creatinine, which was
significantly different between heart and lung transplant patients. In addition, serum
creatinine in transplant recipients is not always a good estimate of creatinine clearance or
glomerular filtration rate. The findings in this study could be the result of altered renal
function and metabolite clearance as opposed to UGT2B7 polymorphism or at least this
could influence the results. Many centers do not measure MPA concentrations and therefore
it would be surprising if AcMPAG concentrations would be measured, being technically
more difficult to collect and measure. Although, if more rigorous larger prospective studies
could confirm that there is an association with this SNP and ultimately outcomes, knowing
the appropriate polymorphisms, in place of specific metabolite concentrations, could prove
valuable.
6. UGT polymorphisms and acute rejection
The majority of acute rejections are seen within the first year, particularly in the first few
months after transplant. Acute rejections vary from b20% in kidney transplants to
approximately 40% in lung transplants [50,51].
Very few studies (see Table 2) have evaluated acute transplant rejection as a primary
outcome in relation to UGT genetic variation. Pharmacodynamic outcomes, such as acute
rejection, were often examined as a secondary outcome in most studies. Almost all studies
have been conducted in kidney transplant recipients. In a study of 95 Caucasian kidney
transplants, receiving tacrolimus and steroids, the relationship between MPA
pharmacokinetics and UGT1A9 −275T>A and −2152C>T was examined and found to be
significant. However, they did not see any difference in episodes of biopsy-proven acute
rejection (BPAR) in a carriers or noncarriers [16]. In another study of 218 mostly Caucasian
kidney transplants, more than 80% received tacrolimus and steroids and several UGT1A9
and UGT2B7 SNPs were studied. No association between these polymorphisms and BPAR
in the first year after transplant was seen [52]. In a large study of 338 kidney transplants,
receiving tacrolimus or cyclosporine, the primary outcome measured was MPA AUC in
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kidney transplant patients. UGT1A9 −275T>A and −2152C>T carriers were found to have a
lower MPA AUC (on day 3) among those receiving concomitant tacrolimus. This study
further examined any influence on the incidence of BPAR among this subset of patients with
acute rejection within 1 year post-transplant. UGT1A9 −275T>A and/or −2152C>T carriers
were at higher risk than noncarriers for having BPAR within 1 year (OR 13.3, 95% CI 1.096
to 162.279, p=0.042) after adjustment for age, sex, number of transplantations, donor type,
induction therapy, panel-reactive antibodies, number of HLA mismatches, CYP3A5
genotype status, and tacrolimus trough levels [31]. Of note is the extremely wide confidence
interval which may be a function of the very small numbers of patients with the variant
genotype (3 out eight patients) who had rejection. These results are preliminary and a much
larger study is required to validate this finding. Similarly, in a study of 68 thoracic
transplants, receiving tacrolimus, cyclosporine or sirolimus with steroids, AcMPAG AUC
concentrations were compared in relation to UGT2B7 SNPs. Outcomes such as acute
rejection were considered secondary measures. An association was seen between these
UGT2B7 SNPs and higher AcMPAG exposure. Acute rejection was associated with an
AcMPAG AUC>50 μg·h/ml. The authors found in a multivariate analysis that UGT2B7
SNPs, −125C and −138A, were significant covariates, along with cyclosporine use for the
development of acute rejection. This analysis only included 3 patients with the −125C and 4
patients with the −138A SNP [49].
7. UGT polymorphisms and MPA toxicities
Gastrointestinal toxicities, such as diarrhea, nausea, vomiting, gastritis and colitis, along
with leukopenia, anemia and thrombocytopenia are the most frequently reported side effects
of MMF. Infection is also a consequence of MMF use. Dose dependency has been
demonstrated mostly for diarrhea and leukopenia. In clinical practice, these side effects
often necessitate a dosage reduction or discontinuation of MMF, putting transplant patients
at risk for acute organ rejection and graft loss [53].
Several studies have evaluated the association between UGT polymorphisms and adverse
effects (see Table 2). Some of these studies are retrospective, and there is a significant
heterogeneity in definitions and assessment of adverse effects different regimens, and time
after transplant. Two studies examined the effect of UGT polymorphisms on the incidence
of diarrhea and other gastrointestinal side effects [48,49]. In a study of 332 kidney transplant
recipients, van Agteren et al. concluded that the UGT2B7 −840G>A polymorphism did not
correlate with either AcMPAG concentrations or the incidence of diarrhea. No association
was found between diarrhea that occurred between month 3 and month 12 after transplant
and AcMPAG concentrations measured at 3 months [48]. Ting et al., in 68 lung and heart
transplant recipients, did not find an association with diarrhea or other reported
gastrointestinal side effects and AcMPAG levels or AcMPAG:MPA metabolic ratio, even
though UGT2B7 2B7 −802C>T and −138A(*2) polymorphisms were found to be associated
with altered pharmacokinetic profiles [49].
Michelson et al. examined the relationship between UGT2B7 and UGT1A9 polymorphisms
and adverse effects one year post-transplantation in 218 kidney transplants, 80% on
tacrolimus with or without steroids. Adverse events were measured as first occurrence of
leukopenia, anemia, thrombocytopenia, diarrhea, nausea/vomiting, or infection. No
association between UGT1A9 −275T>A, UGT1A9 98T>C, and UGT2B7 802C>T SNPs
and adverse events was found [52].
In other studies, diarrhea and gastrointestinal side effects were the outcomes evaluated in
relation to UGT polymorphisms [54,55]. Woillard et al. found that non-carriers of
UGT1A8*2 had a 2-fold higher risk of diarrhea than carriers among 256 renal transplant
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patients. In addition, patients on tacrolimus or sirolimus and MMF had a significantly higher
risk of diarrhea, which is not surprising since these side effects are often seen with these
agents. Other SNPs examined in this study were UGT1A7 (622C>T), UGT1A8*3
(830G>A), UGT1A9 (−275T>A), and UGT2B7 (−840G>A). No association between these
polymorphisms and gastrointestinal side effects was reported [54]. Also among 67 renal
transplant patients, Yang et al. reported that homozygous wild type UGT2B7 −802C>T
showed significantly higher mean gastrointestinal symptom rating scale (GSRS) scores
compared to variant UGT2B7. Higher diarrhea subscores were also reported among non
carriers but this association did not reach statistical significance [55]. In a study, primarily
focused on MPA pharmacokinetics and UGT1A9 SNPs, in 133 Caucasian kidney
transplants, receiving tacrolimus, admissions due to gastrointestinal symptoms, although a
secondary outcome, was reported as higher in carriers of UGT1A9 −275T>A/−2152C>T
[30]. In another study, in which the primary outcome was UGT1A9 SNPs and MPA
pharmacokinetics, in 95 kidney transplants, receiving tacrolimus and steroids, a lower
incidence of diarrhea was observed in carriers of UGT1A9 −275T>A/−2152C>T but did not
reach statistical significance [16]. The reason for these conflicting results in these two
studies is not clear. In a study of 332 renal transplants, no association between leukopenia
with AcMPAG concentrations was seen [48]. Betônico et al. found a higher occurrence of
infections in the first thirty days after transplant among 74 renal transplant patients receiving
MPA 2 g/day and carrying the UGT1A8 277G>A variant [56]. However, this conclusion in
this small retrospective study was based on only 4 patients with this polymorphism. Prausa
et al. compared the incidence of UGT polymorphisms between 16 pediatric kidney
transplant patients, the majority receiving tacrolimus and steroids, that experienced MMF-
related leukopenia and diarrhea versus 22 pediatric kidney transplants without these adverse
effects treated on the same regimen. A greater frequency of these adverse effects was seen in
those with UGT1A9 −331T>C SNPs compared to the control group. The study reported that
homozygous carriers of UGT1A9 −331T>C experienced leukopenia, but not diarrhea,
requiring MMF dosage adjustment [57]. As with other studies the number of patients with a
particular variant is very small.
Ting et al. found a significant association between leukopenia and AcMPAG:MPA
metabolite ratio>2 in a group of 68 thoracic transplants receiving tacrolimus or cyclosporine
or sirolimus with steroids. A significantly decreased incidence of leukopenia was seen in
UGT1A −1813T>C carriers. In addition, the occurrence of infection, which was higher, was
associated with an AcMPAG AUC>50 μg·h/ml and AcMPAG:MPA metabolite ratio>2 [49].
Other MPA related side effects including thrombocytopenia and anemia, have also been
examined. In this same study, anemia was significantly associated with AcMPAG:MPA>2,
and carriers of UGT1A7 Trp208Arg (rs7439366) were found to have a significantly lower
incidence of anemia than non carriers [49]. The clinical role of this SNP needs further
evaluation. They also reported that patients with higher AcMPAG AUC had a higher
occurrence of rejection, infection, leukopenia and anemia. An important consideration with
these findings is that anemia and erythropoietin deficiency is commonly seen in transplant
recipients and could have been influenced by renal dysfunction and/or other drugs. GFR
measurements, for example <30 ml/min vs. >30 ml/min, as opposed to serum creatinine
concentrations, which can be an inaccurate reflection of true renal function, and their
relationship to elevated AcMPAG levels, should be incorporated into any analysis of
AcMPAG concentrations.
8. Conclusion
Based on the current information available, we can establish that UGT variants are not
suitable for individualizing immunosuppressive therapy in transplant patients. There is a
fundamental gap in knowledge related to the number of studies performed and their power
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to identify clinically meaningful associations. A recent report from the FDA Workshop on
Pharmacodynamic and Pharmacogenomic Biomarkers in Solid Organ Transplantation did
not include UGT variants among the potential biomarkers of immunosuppressive therapy
[58]. UGT biomarkers were not regarded as potential promising biomarkers of over-
immunosuppression in a recent review [59].
Acute rejection is probably a very complex phenotype that cannot be predicted by common
genetic variation in one gene involved in the disposition of one of the drugs of
immunosuppressive regimen. Another aspect that may further complicate examination of
these relationships is that the transplanted organ is from a donor with a different genome
than the recipient. Hopefully unbiased, comprehensive interrogation of the genomes of the
patient and the donor could identify novel genes and pathways for further prospective
investigation. To our knowledge, only candidate gene studies have been performed so far,
providing inconclusive and/or conflicting results.
Even using intermediate phenotypes like pharmacokinetic parameters does not seem to be
able to identify strong predictors of interpatient variability in patient exposure to
pharmacologically or toxicologically active drugs or their metabolites. For example, MPA
disposition might be influenced by a number of other variables, such as other
immunosuppressives like tacrolimus, cyclosporine and corticosteroids, as well as inter-
patient variation in excretory pathways. Although therapeutic drug monitoring of MPA is
not a routine procedure to individualize dosing and its role is debated [60,61], perhaps
prospective validation of UGT variants (UGT1A9 −275T>A/−2152C>T, or −440C>T/
−331T>C, UGT1A8 −518C>G(*2)) should be performed in a setting where the endpoint is
the dose needed to achieve MPA levels within a predefined therapeutic window. In the
context of such controlled studies, secondary endpoints of prevention of acute rejection
could be used. From these studies, a combined UGT/MPA level biomarker could be
prospectively tested for its role in avoiding acute rejection.
Many questions about the utilization of UGT SNPs as biomarkers in organ transplantation
remain. What will be required to determine if UGT SNPs are a principal determinant of
MPA pharmacokinetics and pharmacodynamics is to develop more sophisticated
pharmacokinetic and pharmacodynamic models in adequately powered studies that
incorporate these various elements in a large number of patients at different times post
transplant. These models and important parameters then would need to be tested
prospectively in transplant recipients. In addition, novel biology and candidate genes of
transplantation outcomes should be discovered through genome-wide association studies,
run within consortia to overcome the limitation of small and underpowered studies.
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Table 1
MPA clinical pharmacogenetic and pharmacokinetic studies
a
.
UGT SNP (reference number) Number/transplant population/ethnicity/other immunosuppression Significant association/results
1A9 −275T>A/−2152C>T [16] 95 kidney Lower MPA AUC 0–12 h
(day7)with 2 g/day only
Caucasian Lower MPA AUC 6–12 h with 2
g/day only
Tacrolimus and steroids Lower C0 with 2 g/day only
Shorter Tmax with 2 g/day only
Higher Cl/F with 2 g/day only
1A9 −275T>A/−2152C>T [31] 338 kidney Lower MPA AUC/D 0–12 h (day
3 and 1 year) with tacrolimus only
88% Caucasian Lower percent difference in MPA
AUC 0–12 h/D (over 1 year) with
tacrolimus onlyTacrolimus or cyclosporine




1A9 −275T>A/−2152C>T [17] 100 kidneys Lower % of patients within target
AUC 0–12 h range
Tacrolimus and steroids
1A9 −275T>A/−2152C>T [30] 30 kidney Lower AUC 0–12 h
Caucasian Lower AUC 0–6 h
Tacrolimus Lower AUC 6–12 h
1A9 −440C>T [38] 185 kidney Shorter Tmax
Tacrolimus or sirolimus or cyclosporine and steroids
1A9 −440C>T [37] 40 kidney Lower AUC 0–12 h/D
Caucasian
Cyclosporine
1A9 −331T>C [37] 40 kidneys Lower AUC 0–12 h/D
Caucasian
Cyclosporine
1A9 −98T>C (*3) [31] 338 kidney Higher AUC 0–12 h
Tacrolimus or cyclosporine Higher % difference in AUC 0–
12 h/D (over 1 year) with
tacrolimus and cyclosporine88% Caucasian
1A9 −98T>C (*3) [16] 95 kidney Higher AUC 0–12 h with 1 g/day
only
Caucasian Higher AUC 6–12 h
Tacrolimus or steroids
1A9 −98T>C (*3) [38] 185 kidney Higher Cmax/D
Tacrolimus or sirolimus or cyclosporine and steroids With tacrolimus or sirolimus




1A8 −518C>G (*2) [31] 338 kidney Higher AUC 0–12 h (over 1 year)
with cyclosporine
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UGT SNP (reference number) Number/transplant population/ethnicity/other immunosuppression Significant association/results
88% Caucasian
Tacrolimus or cyclosporine and steroids
1A8 −518C>G (*2) [38] 185 kidney Lower C0/D
Tacrolimus or sirolimus or cyclosporine and steroids Lower Cmax/D
Lower AUC 0–12 h/D
With tacrolimus or sirolimus
2B7 −802C>T [37] 40 kidney Higher Cmax/D
Caucasian
Cyclosporine
2B7 −842G>T [34] 92 kidney Higher AcMPAG AUC 0–9 h/D
(1 month) with sirolimus
Tacrolimus or cyclosporine or sirolimus and steroids Higher AcMPAG AUC 0–9 h/D
(3 month) with sirolimus
2B7 −802C>T [49] 68 thoracic Higher AcMPAG AUC 0–12 h
Tacrolimus or cyclosporine Higher AcMPAG/MPA ratio
2B7 − 138A(*2) [49] 68 thoracic Higher AcMPAG AUC 0–12 h
Tacrolimus or cyclosporine Higher AcMPAG/MPA ratio
MPA = mycophenolic acid or mycophenolate; AcMPAG = acyl glucuronide; MPAG = mycophenolic acid glucuronide; AUC = area under the
concentration; Cmax = maximum concentration; C0 = trough concentration; Tmax = time to maximum concentration; CL = clearance; F =
Bioavailability; D = dose.
a
This table lists only studies that reported a statistically significant association between UGT polymorphisms and pharmacokinetic parameters.
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Table 2
MPA-UGT pharmacogenetics and outcomes.
Reference number SNP/objective Study design Study population Clinical outcome(s) Results







Cross-sectional 68 mostly Caucasian
lung or heart transplant
recipients





















Retrospective 74 kidney transplant
patients on MMF for at
least 30 days


















with MPA GI side
effects
Retrospective cohort 256 kidney transplants Diarrhea Non-carriers of the
UGT1A8*2 allele
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Prospective cohort 218 kidney transplant
recipients who
received MMF at a























MPA = mycophenolic acid or mycophenolate; AcMPAG = Acyl glucuronide; MMF = mycophenolate mofetil; AUC = area under the concentration
time curve; BPAR = biopsy proven acute rejection.
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